Sanofi agrees to buy 150 million syringes a year from Unilife; Flexible drug patch conforms to skin;

> Unilife signed a long-term contract to supply prefilled syringes to Sanofi ($SNY), which plans to use them with its blood thinner Lovenox. The French company agreed to buy 150 million syringes a year, and Unilife expects to get between $5 million and $15 million in milestone payments out of the deal, which can be extended through 2024. Story

> Researchers at Virginia Tech and Wake Forest University have developed a flexible drug patch that conforms to the skin. More

> Synta rolled out its Hsp90-inhibitor drug conjugate platform, which helps deliver anticancer drugs directly to tumors. Release

> Mylan ($MYL) is expanding its U.S. transdermal patch facility, investing more than $600 million to double its capacity in St. Albans, VT. Article

> Plandai Biotechnology began clinical trials for its phytofare topical product based on nano-entrapment technology. Release

> NuPathe won a continuation of its patent for an iontophoretic patch with a two-stage sequence to deliver sumatripan through the skin. Its lead product, Zecuity, is approved by the FDA for migraines. Release

> A Johns Hopkins study showed similar effectiveness between two drug delivery systems for chronic obstructive pulmonary disease (COPD)--the Respimat inhaler and the HandiHaler, both from Boehringer Ingelheim. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.